Hollie Franklin, Author at Drugs in Context

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports

José Alexandre Mendonça PhD, Guilherme B Damian MD

Article Type

Case Report

Published

13 Feb 2019

This series of case reports demonstrates the
efficacy of certolizumab pegol in patients with rheumatoid arthritis using gray scale
and power Doppler ultrasonography to monitor disease progression.

Medication adherence and treatment-resistant hypertension: a review

Mohammed Awais Hameed MB, ChB, Indranil Dasgupta DM

Article Type

Review

Published

04 Feb 2019

This article reviews medication nonadherence
in chronic health conditions with particular reference to
treatment-resistant hypertension.

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA

Alpesh Amin MD, MBA, W Richey Neuman MD, MPH, Melissa Lingohr-Smith PhD, Brandy Menges PhD, Jay Lin PhD, MBA

Article Type

Original Research

Published

21 Jan 2019

This article evaluates whether the duration of hospital stay influences venous thromboembolism (VTE) prophylaxis patterns and VTE risk during hospitalization and post-discharge among patients hospitalized for acute illnesses in the USA.

Menopause hormone therapy: latest developments and clinical practice

Tomas Fait MD, PhD

Article Type

Review

Published

02 Jan 2019

Menopause hormone therapy still remains a dominant
therapeutic modality in climacteric medicine. The core medical
skill is the ability to choose the optimal MHT preparation for
the given patient. Such choice is based on an understanding of
various clinical and metabolic effects of MHT depending on the
composition, dosage, and the method of application, this article discusses those choices.

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Marisa C Liu MD, MPH, Krishnansu S Tewari MD

Article Type

Review

Published

27 Dec 2018

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.